Skip to content

LSD: all studies

Page 219 of 282: studies 2,181 to 2,190 of 2,815, newest first. Back to the LSD overview

Research

Treating addiction with psychedelics - are we waking up?

European Psychiatry April 1, 2021 Jackelyne Gabrielle Jesus de Miranda, Mario Barbosa, I. Figueiredo et al.

Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychiatry and neuroscience in the 1950s to 1960s, but the association between classic psychedelics and the emerging counterculture put an end to their research. Modern research with classic psychedelics has reinitiated interest in the treatment of both...

Therapeutic interventions for PTSD – current evidence on the the role of psychedelics

European Psychiatry April 1, 2021 I. Figueiredo, Filipa Viegas, F. Ferreira et al. 2 citations

Introduction Post-traumatic stress disorder (PTSD) is often a chronic condition, despite the existence of evidence-based treatment options. Psychotherapy is the designated first line treatment for PTSD, although high rates of psychiatric and medical comorbidity are observed among patients who have undergone treatment. The psychoactive properties of psychedelics may be of particular interest...

Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?

European Psychiatry April 1, 2021 Nelson Descalço, Ana Beatriz Medeiros, Cátia Fernandes Santos et al. 1 citation

Introduction Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option in treatment-resistant depression. Literature focus mainly on its use on depressive but its...

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

Australian & New Zealand Journal of Psychiatry March 21, 2021 Daniel Perkins, Jerome Sarris, Susan L. Rossell et al. 53 citations

The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on...

DOI: 10.1177/0004867421998785 (opens in new tab) Psilocybin Mental health Psychotherapist Hallucinogen

The Immortality Key: The Secret History of the Religion with No Name

Journal of Psychedelic Studies March 12, 2021 Jerry B. Brown 53 citations

Brain Muraresku is a practicing attorney and a student of ancient languages (Greek, Latin and Sanskrit), whose twelve-year odyssey through the archives of Western religion culminated in the publication of The Immortality Key (TIK).According to Muraresku, this work, which "presents the pagan continuity hypothesis with a psychedelic twist," addresses two fundamental questions: "Before the rise of...

DOI: 10.1556/2054.2021.00170 (opens in new tab) Full text (opens in new tab) Immortality Key lock Epistemology Literature +1

Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials

March 8, 2021 Suresh Muthukumaraswamy, Anna Forsyth, Thomas Lumley 16 citations preprint

There is increasing interest in the potential for psychedelic drugs such as psilocybin, LSD and ketamine to treat a number of mental health disorders. To gain evidence for the therapeutic effectiveness of psychedelics, a number of randomised controlled trials (RCTs) have been conducted using the traditional RCT framework and these trials have generally shown promising results, with large effect...

DOI: 10.31234/osf.io/q2hzm (opens in new tab) Full text (opens in new tab) Blinding Expectancy theory Randomized controlled trial Clinical trial +3

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Hypertension March 8, 2021 Otto Simonsson, Peter S. Hendricks, Robin Carhart-Harris et al. 36 citations

Using data from the National Survey on Drug Use and Health (2005–2014), weighted to be representative of the US adult population, the present study investigated the association between lifetime classic psychedelic use and hypertension in the past year among adults in the United States. The results showed that respondents who reported having used a classic psychedelic at least once in their...

Free energy calculations of the functional selectivity of 5-HT2B G protein-coupled receptor.

PLoS One March 4, 2021 Brandon L Peters, Jinxia Deng, Andrew L Ferguson 4 citations

G Protein-Coupled Receptors (GPCRs) mediate intracellular signaling in response to extracellular ligand binding and are the target of one-third of approved drugs. Ligand binding modulates the GPCR molecular free energy landscape by preferentially stabilizing active or inactive conformations that dictate intracellular protein recruitment and downstream signaling. We perform enhanced sampling...

The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges

Risk Management and Healthcare Policy March 1, 2021 Rafael G. Dos Santos, José Carlos Bouso, Juliana Mendes Rocha et al. 58 citations

Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT2A receptors as their main mechanism of action. Its main effects include changes in perception, cognitive process, and mood. Despite being used for centuries by different cultures in ritual contexts, these substances have currently aroused the interest of science and industry for...

How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence

Anesthesia & Analgesia February 17, 2021 Peter G. Brindley 49 citations

It is tough to write about psychedelics without a few gratuitous puns. Regardless, Michael Pollan’s “How to Change Your Mind” is definitely “mind expanding” and deserves my “highest” recommendation. Published in 2019, this book comprehensively and presciently covers a topic of increasing interest: whether psychedelic agents can revolutionize mental health. Pollan is not a Medical Doctor but is...

DOI: 10.1213/ane.0000000000005349 (opens in new tab) Psilocybin Counterculture Consciousness Psychic +4